Abstract
Arachidonic acid metabolism plays a key role in atherothrombotic events affecting the coronary or cerebrovascular territory, as reflected by experimental studies based on biochemical measurements of eicosanoid biosynthesis and the results of inhibitor trials in these settings. Two cyclooxygenase (COX)-isozymes exist, COX-1 and COX-2, that differ in terms of regulatory mechanisms of expression, tissue distribution, substrate specificity, and susceptibility to inhibition by drugs. Whereas the role of COX-1 expressed in platelets in acute coronary syndromes and ischemic stroke is definitely established through several large clinical studies with aspirin, the role of COX-2 activity in these settings is still unclear, because this enzyme was characterized only recently (1991) and its inhibitors (coxibs) only became available in 1998. In this review, we discuss the different expression profile of COX-2-related enzymes in the cells actively involved in atherothrombosis, the role of these enzymes as cause of plaque “instability”, and the clinical consequences of their inhibition. Recent studies suggest that variable expression of transmembrane and downstream receptors, as well as genetic mutations represent important determinants of the functional consequences of COX-2 expression and inhibition in different clinical settings.
Keywords: Plaque, atherothrombosis, COX-2
Current Vascular Pharmacology
Title: Genetic and Molecular Determinants of Atherosclerotic Plaque Instability
Volume: 8 Issue: 4
Author(s): Francesco Cipollone, Elena Toniato, Stefano Martinotti and Andrea Mezzetti
Affiliation:
Keywords: Plaque, atherothrombosis, COX-2
Abstract: Arachidonic acid metabolism plays a key role in atherothrombotic events affecting the coronary or cerebrovascular territory, as reflected by experimental studies based on biochemical measurements of eicosanoid biosynthesis and the results of inhibitor trials in these settings. Two cyclooxygenase (COX)-isozymes exist, COX-1 and COX-2, that differ in terms of regulatory mechanisms of expression, tissue distribution, substrate specificity, and susceptibility to inhibition by drugs. Whereas the role of COX-1 expressed in platelets in acute coronary syndromes and ischemic stroke is definitely established through several large clinical studies with aspirin, the role of COX-2 activity in these settings is still unclear, because this enzyme was characterized only recently (1991) and its inhibitors (coxibs) only became available in 1998. In this review, we discuss the different expression profile of COX-2-related enzymes in the cells actively involved in atherothrombosis, the role of these enzymes as cause of plaque “instability”, and the clinical consequences of their inhibition. Recent studies suggest that variable expression of transmembrane and downstream receptors, as well as genetic mutations represent important determinants of the functional consequences of COX-2 expression and inhibition in different clinical settings.
Export Options
About this article
Cite this article as:
Cipollone Francesco, Toniato Elena, Martinotti Stefano and Mezzetti Andrea, Genetic and Molecular Determinants of Atherosclerotic Plaque Instability, Current Vascular Pharmacology 2010; 8 (4) . https://dx.doi.org/10.2174/157016110791330825
DOI https://dx.doi.org/10.2174/157016110791330825 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Docking, Synthesis and Anti-Diabetic Activity of Novel Sulfonylhydrazone Derivatives Designed as PPAR-Gamma Agonists
Current Topics in Medicinal Chemistry Recent Advances in Bioreactors in Tissue Engineering and Regenerative Medicine
Current Tissue Engineering (Discontinued) Opioid-induced Cardioprotection
Current Pharmaceutical Design Adrenoceptor Polymorphisms in Hypertension and Diabetes with Obesity- Update in 2013
Current Hypertension Reviews Treatment Strategies Against Diabetic Foot Ulcer: Success so Far and the Road Ahead
Current Diabetes Reviews Novel 4-Oxothienopyrimidinyl Propanoic Acid Derivatives as AMPActivated Protein Kinase (AMPK) Activators
Letters in Drug Design & Discovery Mediterranean Diet and Hypertension; From the Clinical and Epidemiologic Evidences to Prevention
Current Hypertension Reviews Platelets and Vascular Risk: An Option for Treatment
Current Pharmaceutical Design Role of Vasa Vasorum in Arterial Disease: A Re-emerging Factor
Current Cardiology Reviews The Association of Fractalkine Receptor (T280M) Polymorphism in the Pathogenesis of Acute Coronary Syndrome in the Egyptian Population
Current Pharmaceutical Biotechnology Chemokines and Chemokine Receptors Blockers as New Drugs for the Treatment of Chronic Obstructive Pulmonary Disease
Current Medicinal Chemistry Why is the Inhibition of the Renin-Angiotensin System Effective for Preventing Cardiac Events in Patients with Coronary Risk Factors or Coronary Artery Disease?
Current Cardiology Reviews MTHFR Gene Polymorphism and Diabetic Retinopathy
Current Diabetes Reviews Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction
Current Topics in Medicinal Chemistry Intravenous Thrombolysis with rt-PA in Acute Stroke Patients Aged ≥80 Years
Letters in Drug Design & Discovery The Coronary Collateral Circulation in Man
Current Cardiology Reviews Biomarkers of Aspirin Resistance
Recent Patents on Biomarkers Activation of the Innate Immune System in Atherosclerotic Disease
Current Pharmaceutical Design Clinical Pharmacogenetics and Potential Application in Personalized Medicine
Current Drug Metabolism Gender Bias in Acute Coronary Syndromes
Current Vascular Pharmacology